ArticleFrontiers in immunology2021
A Combination Adjuvant for the Induction of Potent Antiviral Immune Responses for a Recombinant SARS-CoV-2 Protein Vaccine.
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Mucosal immunity and vaccine development.Signal transduction and targeted therapy · 2026Pooled it
- How vaccine research took me on an international journey.Human vaccines & immunotherapeutics · 2026Article
- Nanoemulsion adjuvanted COBRA HA vaccine enhances protective antibody titers against H1N1 and H3N2 influenza viruses.Human vaccines & immunotherapeutics · 2026Article
- Spatiotemporal heterologous vaccination relies on type I interferons at priming to enhance mucosal immunity.EMBO molecular medicine · 2026Article
- Evaluation of new adjuvants in enhancing the immune response to a candidate of Severe Fever with Thrombocytopenia Syndrome Virus vaccine.bioRxiv : the preprint server for biology · 2026Article
- A dual-adjuvanted HA stem nanoparticle vaccine elicits a multifunctional antibody response that is associated with protection in newborn monkeys.Cell reports. Medicine · 2026Article
- Mucosal vaccination with long-form TSLP induces migratory cDC1-mediated adaptive immunity against SARS-CoV-2 infection.Journal of virology · 2025Article
- Genetic adjuvants: A paradigm shift in vaccine development and immune modulation.Molecular therapy. Nucleic acids · 2025Review
- Advancements in Nanoemulsion-Based Drug Delivery Across Different Administration Routes.Pharmaceutics · 2025Review
- Enhancing functional antibody responses against HIV envelope V1V2 through vaccine formulations.Frontiers in immunology · 2025Article
- Nanotechnology-driven advances in intranasal vaccine delivery systems against infectious diseases.Frontiers in immunology · 2025Review
- Induction of protective immune responses at respiratory mucosal sites.Human vaccines & immunotherapeutics · 2024Review
- Enhanced mucosal SARS-CoV-2 immunity after heterologous intramuscular mRNA prime/intranasal protein boost vaccination with a combination adjuvant.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- A Dual-Adjuvanted Parenteral-Intranasal Subunit Nanovaccine generates Robust Systemic and Mucosal Immunity Against SARS-CoV-2 in Mice.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Preclinical evaluation of a universal inactivated influenza B vaccine based on the mosaic hemagglutinin-approach.NPJ vaccines · 2024Article
- Nanomedicine for the Treatment of Viral Diseases: Smaller Solution to Bigger Problems.Pharmaceutics · 2024Review
- Article
- Multicomponent intranasal adjuvant for mucosal and durable systemic SARS-CoV-2 immunity in young and aged mice.NPJ vaccines · 2023Article
- Virus-like Particles of Nodavirus Displaying the Receptor Binding Domain of SARS-CoV-2 Spike Protein: A Potential VLP-Based COVID-19 Vaccine.International journal of molecular sciences · 2023Article
- A multicomponent intranasal adjuvant drives durable humoral, cellular, and mucosal immune responses to SARS-CoV-2 in young and aged mice.Research square · 2023Article
Corrections and comments
- Update of
Authors and funding
11 authors.
Funding
Abstract
Several SARS-CoV-2 vaccines have received EUAs, but many issues remain unresolved, including duration of conferred immunity and breadth of cross-protection. Adjuvants that enhance and shape adaptive immune responses that confer broad protection against SARS-CoV-2 variants will be pivotal for long-term protection as drift variants continue to emerge. We developed an intranasal, rationally designed adjuvant integrating a nanoemulsion (NE) that activates TLRs and NLRP3 with an RNA agonist of RIG-I (IVT DI). The combination adjuvant with spike protein antigen elicited robust responses to SARS-CoV-2 in mice, with markedly enhanced T
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.